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Accumulated evidence implicates sympathetic activation as inducing oxidative
stress and systemic inflammation, which in turn lead to hypertension, endothelial
dysfunction, and atherosclerosis in obstructive sleep apnea (OSA). Statins through
their pleiotropic properties may modify inflammation, lipid profile, and
cardiovascular outcomes in OSA.
METHODS:
This multicenter, randomized, double-blind study compared the effects of
atorvastatin 40 mg/day versus placebo over 12 weeks on endothelial function (the
primary endpoint) measured by peripheral arterial tone (PAT). Secondary
endpoints included office blood pressure (BP), early carotid atherosclerosis,
arterial stiffness measured by pulse wave velocity (PWV), and metabolic
parameters.
RESULTS:
51 severe OSA patients were randomized. Key demographics for the study
population were age 54 +/- 11 years, 21.6% female, and BMI 28.5 +/- 4.5 kg/m(2).
In intention to treat analysis, mean PAT difference between atorvastatin and
placebo groups was 0.008 (-0.29; 0.28), P = 0.979. Total and LDL cholesterol
significantly improved with atorvastatin. Systolic BP significantly decreased with
atorvastatin (mean difference: -6.34 mmHg (-12.68; -0.01), P = 0.050) whereas
carotid atherosclerosis and PWV were unchanged compared to the placebo group.
CONCLUSION:
In OSA patients, 3 months of atorvastatin neither improved endothelial function
nor reduced early signs of atherosclerosis although it lowered blood pressure and
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